Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRIX Nurix Therapeutics

Trading 09-01 13:19:11 EDT

25.80

+0.02

+0.08%

High26.00	Low25.47	Vol353.11K
Open25.47	D1 Closing25.78	Amplitude2.06%
Mkt Cap2.67B	Tradable Cap2.45B	Total Shares103.41M
T/O9.07M	T/O Rate0.37%	Tradable Shares95.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":25.8,"timestamp":1788283145159,"preClose":25.78,"halted":0,"volume":353109,"delay":0,"changeRate":0.000775795190069805,"floatShares":95045157,"shares":103405813,"eps":-3.410201,"marketStatus":"Trading","change":0.02,"latestTime":"09-01 13:19:11 EDT","open":25.47,"high":26,"low":25.47,"amount":9067614.895785,"amplitude":0.020559,"askPrice":25.87,"askSize":110,"bidPrice":25.78,"bidSize":28,"shortable":3,"etf":0,"ttmEps":-3.410201,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":25.78,"preHourTrading":{"tag":"盘前","latestPrice":25.01,"preClose":25.78,"latestTime":"09:12 EDT","volume":2448,"amount":63089.86824,"timestamp":1788268372481,"change":-0.77,"changeRate":-0.029868,"amplitude":0.039178},"postHourTrading":{"tag":"盘后","latestPrice":25.78,"preClose":25.78,"latestTime":"19:30 EDT","volume":159098,"amount":4101551.937584,"timestamp":1788219002486,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.580345,"impliedVol":0.6597,"impliedVolPercentile":0.5198},"requestUrl":"/m/hq/s/NRIX","defaultTab":"news","newsList":[{"id":"2664562658","title":"Nurix Therapeutics to Participate in Upcoming September Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664562658","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664562658?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354077/0/en/nurix-therapeutics-to-participate-in-upcoming-september-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663097223","title":"Nurix Advances NX-5948 Combo Trial in B-Cell Cancers, Setting Up Key Catalyst for NRIX","url":"https://stock-news.laohu8.com/highlight/detail?id=2663097223","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663097223?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:31","pubTimestamp":1787934694,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics, Inc. ($NRIX) announced an update on their ongoing clinical study. The Phase 1b/2 study “An Open-label, Multicenter Phase 1b/2 S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nurix-advances-nx-5948-combo-trial-in-b-cell-cancers-setting-up-key-catalyst-for-nrix?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nurix-advances-nx-5948-combo-trial-in-b-cell-cancers-setting-up-key-catalyst-for-nrix?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175580","title":"BeOne Medicines' Tacabrutideg Presents 'Sizable Opportunity' in CSU, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175580","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175580?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:12","pubTimestamp":1787670744,"startTime":"0","endTime":"0","summary":"BeOne Medicines'  BTK degrader tacabrutideg presents a \"sizable opportunity\" in chronic spontaneous urticaria or CSU, RBC Capital Markets said in a Tuesday note.CSU is an inflammatory skin condition that can be a major market with peak sales estimates of about $3 billion, the brokerage said. BTK degraders have the potential to top BTK inhibitors in CSU, likely exceeding inhibitors in terms of potency and effect durability, RBC noted.Nurix Therapeutics  has reported that its BTK degrader bexobrutideg demonstrated greater potency in CSU compared with Novartis'  BTK inhibitor remibrutinib, and RBC sees tacabrutideg's overall efficacy profile as \"broadly comparable\" with bexobrutideg, according to the note.BeOne Medicines is planning to advance tacabrutideg to phase 2 studies in CSU, RBC noted.RBC has an outperform rating and $450 price target on BeOne Medicines.Price: 376.42, Change: +4.44, Percent Change: +1.19","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002141913.USD","BK4532","IE00B4R5TH58.HKD","BK4585","LU0070302665.USD","MEDX","BK4578","MDCO","IE00BFTCPJ56.SGD","BK4007","IE00BJT1NW94.SGD","NVS","LU0208291251.USD","LU0320765489.SGD","NRIX","ONC","LU0211331839.USD","IE0009355771.USD","BK4588","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4139","PPH","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660863842","title":"Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660863842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660863842?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUA4NZZHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456397","title":"Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456397","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456397?lang=en_us&edition=fundamental","pubTime":"2026-08-18 09:23","pubTimestamp":1787016212,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has drawn investor attention after two key events. The company reported a new Phase 3 trial for its BTK degrader bexobrutideg and a separate US$10 million milestone payment from collaborator Sanofi.\nSee our latest analysis for Nurix Therapeutics.\nAgainst this backdrop, Nurix Therapeutics’ recent clinical milestones and collaboration progress have coincided with strong momentum, with a 30 day share price return of 17.52% and a 1 year total shareholder return of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-starts-phase-3-and-lands-sanofi-mile","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-starts-phase-3-and-lands-sanofi-mile","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SNYNF","NRIX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659518428","title":"Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche","url":"https://stock-news.laohu8.com/highlight/detail?id=2659518428","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659518428?lang=en_us&edition=fundamental","pubTime":"2026-08-13 08:38","pubTimestamp":1786581503,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics recently reported earning a US$10 million milestone payment from Sanofi for advancing its oral STAT6 degrader into a Phase 1 trial, while also enrolling the first patient in a global Phase 3 study of its BTK degrader bexobrutideg in partnership with Roche for relapsed or refractory CLL/SLL.\nTogether, these updates highlight how Nurix’s DEL-AI protein degradation platform is now translating into late-stage clinical programs and tangible partnership revenues under its Sanofi...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-is-up-60-after-milestone-from-sanofi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-is-up-60-after-milestone-from-sanofi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","NRIX","SNYNF","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658958987","title":"Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658958987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658958987?lang=en_us&edition=fundamental","pubTime":"2026-08-11 00:44","pubTimestamp":1786380254,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics'  STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi , RBC Capital Markets said in a Monday research note.The investment firm said limited preclinical data suggest NX-3911 could be on relatively equal footing with Kymera Therapeutics'  KT-621, supporting higher value for Nurix when factoring in immunology and inflammation optionality across NX-3911, bex-deg and the rest of its pipeline.RBC expects NX-3911 to receive increased attention ahead of Kymera's STAT6 atopic dermatitis data expected by year-end, which could provide positive readthrough for Nurix's program. It noted that Sanofi is leading early clinical development of NX-3911, with a proof-of-concept dataset potentially available in the first half of 2027.The brokerage said bex-deg's chronic lymphocytic leukemia opportunity remains the core of its bullish thesis on Nurix, while the company also has optionality from its","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4566","BK4550","BK4588","LU1839511570.USD","BK4139","IE00BKVL7J92.USD","LU0965509101.SGD","NRIX","LU1430594728.SGD","IE00BZ1G4Q59.USD","BMED","LU1066053197.SGD","LU1934455194.USD","LU1037948897.HKD","LU0823416689.USD","LU2324357040.USD","IE00BSNM7G36.USD","LU2089984988.USD","SNY","LU0109394709.USD","LU1674673428.USD","LU1585245621.USD","LU1571399168.USD","IE00B19Z3581.USD","LU0058720904.USD","MEDI","LU0965508806.USD","IE0002270589.USD","SG9999015945.SGD","GILD","TMED","LU1057294990.SGD","LU1934455863.HKD","BK4532","LU0320765992.SGD","SG9999015986.USD","LU0882574055.USD","LU1023059063.AUD","KYMR","BK4585","LU2112291526.USD","BIB","IBBQ","IE00B3T34201.USD","LU1934455277.USD","BK4007","TBXU","IE00B7SZLL34.SGD","BBH","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658958501","title":"Nurix Therapeutics is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2658958501","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658958501?lang=en_us&edition=fundamental","pubTime":"2026-08-11 00:39","pubTimestamp":1786379940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658980223","title":"RBC Adjusts PT on Nurix Therapeutics to $36 From $33, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980223","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658980223?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:57","pubTimestamp":1786359455,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has an average rating of buy and mean price target of $33.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578076","title":"How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578076","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578076?lang=en_us&edition=fundamental","pubTime":"2026-08-06 03:23","pubTimestamp":1785957818,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics recently reported two key milestones: a US$10 million payment under its Sanofi collaboration tied to a first-in-human STAT6 degrader trial and the first patient enrolled in a global Phase 3 DAYBreak CLL-306 study of bexobrutideg with Roche in relapsed or refractory CLL/SLL.\nThese updates highlight how Nurix’s DEL-AI discovery platform and partnership model can convert early discovery work into late-stage trials and substantial future milestone eligibility, while preserving...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/how-investors-may-respond-to-nurix-therapeutics-nrix-advanci","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/how-investors-may-respond-to-nurix-therapeutics-nrix-advanci","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ISBC","BK4211","NRIX","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543400","title":"Nurix CSO Gwenn Hansen Sells 4,111 Shares for $100,068.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543400","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543400?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:40","pubTimestamp":1785926419,"startTime":"0","endTime":"0","summary":"Nurix CSO Gwenn Hansen sells 4,111 shares for $100,068.32Nurix Therapeutics Chief Scientific Officer Gwenn Hansen sold 4,111 common shares on Aug. 4.Sales priced at USD 23.87 and USD 24.64 per share.P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL2t92fg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix CSO Gwenn Hansen Sells 4,111 Shares for $100,068.32","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656185557","title":"Nurix Therapeutics Price Target Maintained with a $34.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2656185557","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656185557?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:15","pubTimestamp":1785856500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530583","title":"Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a Stat6 Degrader","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530583?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA9PCZSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530245","title":"Nurix Therapeutics - Has Received About $139 Mln Under 2019 Sanofi Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530245","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530245?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA9PCZSZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656212530","title":"Nurix Therapeutics - Eligible for About $453 Mln in Future Stat6 Milestones and Potential Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2656212530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656212530?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA9PCZSZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656572531","title":"Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656572531","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656572531?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:42","pubTimestamp":1785836547,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics  said Tuesday it enrolled the first participant in a Phase 3 clinical trial testing its experimental drug bexobrutideg as a treatment for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.The global study will compare bexobrutideg with the investigator's choice of pirtobrutinib or idelalisib plus rituximab in approximately 620 patients whose disease progressed after prior treatment with a Bruton's tyrosine kinase inhibitor and a BCL-2 inhibitor, the company said.Nurix said the trial's co-primary endpoints are overall response rate and progression-free survival, with overall survival among the key secondary endpoints.The company said the study is intended to support potential regulatory approval of bexobrutideg if successful.Shares of the company were up 2.3% in Tuesday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656616584","title":"Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 Daybreak Cll-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2656616584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656616584?lang=en_us&edition=fundamental","pubTime":"2026-08-04 13:00","pubTimestamp":1785819601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA69NM7P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656307201","title":"Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 16,589 Common Shares Worth $382,324.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2656307201","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656307201?lang=en_us&edition=fundamental","pubTime":"2026-08-04 05:52","pubTimestamp":1785793960,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Chief Legal Officer Christine Ring disposes of 16,589 common shares worth $382,324.26Nurix Therapeutics Chief Legal Officer Christine Ring reported a net reduction in common stock h","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL4QpwSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 16,589 Common Shares Worth $382,324.26","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655488975","title":"Nurix Therapeutics is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2655488975","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655488975?lang=en_us&edition=fundamental","pubTime":"2026-07-29 01:10","pubTimestamp":1785258600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653760554","title":"Nurix Therapeutics is Maintained at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2653760554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653760554?lang=en_us&edition=fundamental","pubTime":"2026-07-23 02:54","pubTimestamp":1784746440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings(END) Dow Jones NewswiresJuly 22, 2026 14:54 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":-0.0187},{"period":"1month","weight":0.1107},{"period":"3month","weight":0.5748},{"period":"6month","weight":0.5855},{"period":"1year","weight":1.7602},{"period":"ytd","weight":0.359}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0268},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1196},{"period":"1year","weight":0.1891},{"period":"ytd","weight":0.1248}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074756},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.011931},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064842},{"month":4,"riseRate":0.5,"avgChangeRate":-0.023295},{"month":5,"riseRate":0.5,"avgChangeRate":0.009892},{"month":6,"riseRate":0.666667,"avgChangeRate":0.159386},{"month":7,"riseRate":0.5,"avgChangeRate":0.064005},{"month":8,"riseRate":0.571429,"avgChangeRate":0.029558},{"month":9,"riseRate":0.166667,"avgChangeRate":0.009437},{"month":10,"riseRate":0.5,"avgChangeRate":0.003905},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}